N-(3-amino-4-fluorophenyl)-3-dimethylaminobenzamide | 250683-79-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-amino-4-fluorophenyl)-3-dimethylaminobenzamide
• 英文别名: N-(3-amino-4-fluorophenyl)-3-(dimethylamino)benzamide
• CAS: 250683-79-5
• 化学式: C₁₅H₁₆FN₃O
• 分子量: 273.31
• InChiKey: GLDIFWCBZKQVMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  58.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,4-二甲氧基苯甲酰氯 、 N-(3-amino-4-fluorophenyl)-3-dimethylaminobenzamide 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-[5-(3-dimethylaminobenzamido)-2-fluorophenyl]-3,4-dimethoxybenzamide
  参考文献：
  名称：

  A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis

  摘要：

  A novel p38 MAP kinase inhibitor structural class was discovered through selectivity screening. The rational analogue design, synthesis and structure-activity relationship of this series of bisamide inhibitors is reported. The inhibition in vitro of human p38alpha enzyme activity and lipopolysaccharide-induced tumour necrosis factor-alpha release is described for the series. The activity in vivo and pharmacokinetic properties are exemplified for the more potent analogues. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.08.006
• 作为产物：
  描述：

  3-二甲基氨基苯甲酰氯 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 N-(3-amino-4-fluorophenyl)-3-dimethylaminobenzamide
  参考文献：
  名称：

  A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis

  摘要：

  A novel p38 MAP kinase inhibitor structural class was discovered through selectivity screening. The rational analogue design, synthesis and structure-activity relationship of this series of bisamide inhibitors is reported. The inhibition in vitro of human p38alpha enzyme activity and lipopolysaccharide-induced tumour necrosis factor-alpha release is described for the series. The activity in vivo and pharmacokinetic properties are exemplified for the more potent analogues. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.08.006

文献信息

• Benzamide derivatives for the treatment of diseases mediated by cytokines
  申请人：AstraZeneca AB

  公开号：US06465455B1

  公开（公告）日：2002-10-15

  The invention concerns amide derivatives of Formula (I) wherein: R1 and R2 include hydroxy, C1-6alkoxy, mercapto, C1-6akylthio, amino and heterocyclyl; m and p are independently 0-3; R3 is halo, cyano or C1-6alkoxy; q is 0-4; and R4 is aryl or cycloalkyl wherein R4 is optionally substituted with up to 3 substituents having any value defined for each R1 group; or a pharmaceutically-acceptable salt or in-vivo-cleavable ester thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

  本发明涉及式（I）的酰胺衍生物，其中：R1和R2包括羟基，C1-6烷氧基，巯基，C1-6烷基硫基，氨基和杂环基；m和p独立地为0-3；R3为卤素，氰基或C1-6烷氧基；q为0-4；R4为芳基或环烷基，其中R4可以用每个R1群定义的任何值最多被取代3个取代基；或其药学上可接受的盐或体内可裂解酯；制备它们的方法，包含它们的制药组合物以及它们在治疗由细胞因子介导的疾病或医疗情况中的用途。
• BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES
  申请人：AstraZeneca AB

  公开号：EP1077930A1

  公开（公告）日：2001-02-28
• US6465455B1
  申请人：——

  公开号：US6465455B1

  公开（公告）日：2002-10-15
• [EN] BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES<br/>[FR] DERIVES DE BENZAMIDE SERVANT A TRAITER DES MALADIES PROVOQUEES PAR DES CYTOKINES
  申请人：ASTRAZENECA AB

  公开号：WO1999059960A1

  公开（公告）日：1999-11-25

  (EN) The invention concerns amide derivatives of Formula (I) wherein: R1 and R2 include hydroxy, C1-6alkoxy, mercapto, C1-6alkylthio, amino and heterocyclyl; m and p are independently 0-3; R3 is halo, cyano or C1-6alkoxy; q is 0-4; and R4 is aryl or cycloalkyl wherein R4 is optionally substituted with up to 3 substituents having any value defined for each R1 group; or a pharmaceutically-acceptable salt or $i(in-vivo)-cleavable ester thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.(FR) L'invention concerne des dérivés d'amide représentés par la formule I formule (I) dans laquelle R1 et R2 représentent hydroxy, alkoxy C1-C6, mercapto, alkylthio C1-C6, amino et hétérocyclyle; m et p sont indépendamment 0-3; R3 représente halo, cyano ou alkoxy C1-C6; q est 0-4; R4 représente aryle ou cycloalkyle et est éventuellement substitué par 3 substituants maximum possédant toute valeur définie pour chaque groupe R1; ou un sel acceptable sur le plan pharmaceutique ou un de leurs esters pouvant être clivé $i(in vivo); leurs procédés de préparation, compositions pharmaceutiques les contenant et leur utilisation pour le traitement de maladies ou d'états pathologiques pour lesquels les cytokines jouent un rôle d'intermédiaire.